278,775 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Purchased by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC acquired a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 278,775 shares of the company’s stock, valued at approximately $1,419,000. Parkman Healthcare Partners LLC owned about 0.94% of Eliem Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ELYM. Bank of New York Mellon Corp bought a new stake in shares of Eliem Therapeutics during the 2nd quarter worth approximately $134,000. Rhumbline Advisers purchased a new stake in Eliem Therapeutics in the second quarter worth $59,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eliem Therapeutics during the second quarter valued at $89,000. Renaissance Technologies LLC boosted its stake in shares of Eliem Therapeutics by 248.5% during the second quarter. Renaissance Technologies LLC now owns 37,000 shares of the company’s stock valued at $263,000 after purchasing an additional 26,383 shares during the period. Finally, Ally Bridge Group NY LLC bought a new position in shares of Eliem Therapeutics in the second quarter worth about $3,555,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Stock Performance

Shares of NASDAQ:ELYM opened at $3.15 on Wednesday. The firm has a market cap of $93.72 million, a PE ratio of -6.15 and a beta of -0.39. The firm’s 50 day simple moving average is $4.30 and its 200-day simple moving average is $6.34. Eliem Therapeutics, Inc. has a one year low of $2.35 and a one year high of $11.55.

Eliem Therapeutics Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.